An observational study in Crohn's Disease, sponsored by Gerhard Rogler. Terminated at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-04.
Sponsored by Gerhard Rogler · Observational
The investigators will study the effect of Adalimumab on the bone microstructure.
1,880 studies on the registry are indexed under Crohn Disease; 461 are open to participants now.
This study's enrollment of 34 is below the median of 162 across 608 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →Gerhard Rogler is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients cohort of the University Hospital Zurich
Exclusion criteria:
Adalimumab will be applied according to manufacture's instruction and official guidelines.
This study is terminated, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gerhard Rogler